Danse Bi, MD
Gastroenterology · Los Angeles, CANPI 1659804649
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,200 of the $3,543 with a category attached, or 62.1%. 9 manufacturers reported payments, led by Apollo Endosurgery US Inc at 24.8% of the total.
Across 56 payments — averaging $63.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apollo Endosurgery US Inc$878
- Boston Scientific$686
- Johnson & Johnson$644
- Olympus Corporation Of The Americas$446
- Fujifilm Healthcare Americas Corporation$390
- AbbVie$172
- plus $327 from 3 others
What the payments were for
- Travel & lodging$1,34238%
- Food & beverage$2,20062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apollo Endosurgery US Inc | 6 | $878 |
| Boston Scientific | 6 | $686 |
| Johnson & Johnson | 31 | $644 |
| Olympus Corporation Of The Americas | 2 | $446 |
| Fujifilm Healthcare Americas Corporation | 4 | $390 |
| AbbVie | 4 | $172 |
| Sanofi | 1 | $127 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Medtronic | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,543 in reported general payments places this provider in the 60th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 39 | $605 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Los Angeles
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$1.9M
- Sadeea AbbasiLos Angeles$556K
- Gil MelmedLos Angeles$467K
- Venkataraman MuthusamyLos Angeles$297K
- Caroline HwangLos Angeles$279K
- Adarsh ThakerLos Angeles$241K
- Andres YarurLos Angeles$218K
- Joseph PisegnaLos Angeles$210K
- Steven-Huy HanLos Angeles$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.